Stock Markets
Cantor Fitzgerald starts ADC Therapeutics with Overweight rating
On Thursday, Cantor Fitzgerald began coverage on shares of ADC Therapeutics (NYSE:ADCT), assigning an Overweight rating to the stock. The firm highlighted the biotechnology company’s potential within the antibody-drug conjugate (ADC) sector, noting its modest valuation in comparison to its prospects.
ADC Therapeutics’ platform utilizes powerful payloads like pyrrolobenzodiazepine (PBD) and exatecan, which are designed to target and kill cancer cells. Cantor Fitzgerald pointed out that while the potency of these drugs can lead to toxicity, it also contributes to their efficacy. The firm’s decision to rate the company as Overweight is supported by data from ADC Therapeutics’ ZYNLONTA and other drug candidates, which suggest an acceptable safety profile for their treatments.
ZYNLONTA, specifically, is an ADC that has been developed for the treatment of certain types of lymphoma. The endorsement from Cantor Fitzgerald comes as the company continues to advance its pipeline of ADCs, aiming to provide new therapies in the oncology space.
The Overweight rating indicates that Cantor Fitzgerald believes ADC Therapeutics’ stock could outperform the average return of the stocks that the firm covers. This outlook is based on the company’s innovative ADC platform and the clinical data supporting the safety of its drug candidates.
ADC Therapeutics is part of a growing industry focused on targeted cancer therapies. The company’s progress and potential in developing treatments that can precisely attack cancer cells while minimizing harm to healthy tissues have positioned it as a notable player in the pharmaceutical market.
InvestingPro Insights
Cantor Fitzgerald’s positive outlook on ADC Therapeutics (NYSE:ADCT) is bolstered by the company’s advances in the antibody-drug conjugate (ADC) sector. Still, investors should consider several financial metrics and market performances that InvestingPro has highlighted.
With a market capitalization of $320.43 million, ADC Therapeutics is navigating through a challenging financial landscape, as evidenced by a negative P/E ratio of -1.22 and a concerning gross profit margin of -86.89% for the last twelve months as of Q1 2024. The company’s stock price has experienced significant volatility, with a large uptick over the last six months, yet it has seen a substantial decline over the last month.
InvestingPro Tips suggest that ADC Therapeutics is quickly burning through cash and analysts do not anticipate the company will be profitable this year. Moreover, the stock has taken a big hit over the last week, which may be a point of consideration for investors.
On a more positive note, the firm’s liquid assets exceed its short-term obligations, providing some financial stability in the near term. For those interested in deeper analysis, InvestingPro offers additional tips on ADC Therapeutics, which can be found on their platform. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and discover the full range of insights that could guide investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
US stocks slightly lower after Christmas holiday
Investing.com– U.S. stocks were slightly lower on Thursday, though trading volumes were thin a day after the Christmas holiday.
At of 12:58 ET (17:58 GMT), the fell 0.10%, the was down 0.1%, while the declined 0.01% or 6 points.
Jobless claims in U.S. dip to one-month low
The weekly U.S. jobless claims data released before the market opened on Thursday and saw a one-month low dip.
The Labor Department reported a decrease of 1,000 in initial applications for state unemployment benefits, bringing the seasonally adjusted figure to 219,000 for the week that ended on December 21. This figure is lower than the 224,000 claims that economists had predicted for the same week.
Meanwhile, the number of individuals receiving benefits after their first week of aid, which serves as an indication of hiring, increased by 46,000. This brought the seasonally adjusted total to 1.910 million for the week that ended on December 14, the highest since November 2021. Economists had previously anticipated the number of these continued claims to be 1.880 million.
“We do not think that this week’s data will move the needle for any of them, but more prints in line with the tone of this week’s data may motivate the doves on the Committee to speak up,” Jefferies said in a recent note.
Tech stocks flat despite Apple upgrade
The major tech giants were mostly down after the markets opened, with Apple marginally higher despite an upgrade from tech-bull Wedbush.
Apple Inc (NASDAQ:) gained 0.2% affter Wedbush raised its price target on Apple to $325 from $300 banking on transformative AI-driven iPhone upgrade cycle poised to fuel growth into 2025.
“We believe Apple is heading into a multi-year AI driven iPhone upgrade cycle that is still being underestimated by the Street,” Wedbush said in a recent note.
Crypto-related stocks slip as bitcoin skids, but KULR Technology surges on BTC purchase
Crypto-related stocks including MicroStrategy Incorporated (NASDAQ:), Coinbase Global Inc (NASDAQ:), and Riot Platforms (NASDAQ:) followed bitcoin lower as the most valuable cryptocurrency fell more than 2%.
KULR Technology jumped 30% after the space technology company bought about 217 bitcoin and detailed plans to allocate up to 90% of its excess cash to bitcoin.
Stock Markets
Lichen China Limited announces $2.8 million share sale
XIAMEN, China – Lichen China Limited (NASDAQ:LICN), a company specializing in financial and taxation services, has announced a definitive agreement with several investors for a registered direct offering. The offering involves the sale of 20 million Class A ordinary shares, or pre-funded warrants as an alternative, at a price of $0.14 per share. This transaction is expected to yield approximately $2.8 million in gross proceeds for the company. The offering comes as the company maintains strong financial fundamentals, with InvestingPro data showing an impressive gross profit margin of 61% and a healthy current ratio of 17.55x.
The closing of the sale is anticipated on or about December 27, 2024, pending the fulfillment of customary conditions. Univest Securities, LLC is the sole placement agent for the offering, which is being conducted under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on March 1, 2024.
Investors can access the final prospectus supplement and accompanying prospectus, detailing the offering’s terms, on the SEC’s website once filed. The offering is only valid in jurisdictions where it is lawful, and the securities cannot be sold in any jurisdiction where such an offer, solicitation, or sale would be illegal prior to registration or qualification under the applicable securities laws.
Lichen China, with over 18 years of experience, has established a reputation for providing professional and high-quality financial and taxation solutions in China. The company also offers education support services and software and maintenance services under the “Lichen” brand. Despite the stock’s significant decline of 89% year-to-date, InvestingPro analysis indicates the company is currently undervalued, with robust revenue growth of 25% in the last twelve months. Get access to 16 additional ProTips and comprehensive financial analysis with an InvestingPro subscription.
The company’s press release contains forward-looking statements that involve risks and uncertainties. While Lichen China believes the expectations reflected in these statements are reasonable, they caution that actual results may differ materially. Trading at a P/E ratio of 6.4x and with a market capitalization of $8.17 million, investors are encouraged to review factors that may affect the company’s future results in its registration statement and other SEC filings.
This news article is based on a press release statement from Lichen China Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
2024 Year-End NAIC Designations for STACR REMIC Trust, STACR Trust, and STACR Debt Notes
MCLEAN, Va., Dec. 26, 2024 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: OTC:) today published on its website the National Association of Insurance Commissioners (NAIC) 2024 filing year designations for certain STACR REMIC Trust, STACR Trust, and STACR Debt Notes (collectively, STACR Notes).
Overall, of the 209 reviewed STACR Notes, all have achieved NAIC 1 Designation including all A1, M1 and M2 Notes offered through 2024 STACR transactions. In addition, 10 of the 2024 NAIC 1 Designations are upgrades from their 2023 NAIC 2 Designations. The below table details the upgrades:
CUSIP | Deal Name | 2023 Year-End NAIC Designation | 2023 Year-End NAIC Designation Modifier | 2024 Year-End NAIC Designation | 2024 Year-End NAIC Designation Modifier |
35564KB57 | STACR 2022-HQA2 M2B | 2 | B | 1 | E |
35564KB65 | STACR 2022-HQA2 M2 | 2 | A | 1 | D |
35564KE62 | STACR 2022-HQA3 M2B | 2 | C | 1 | F |
35564KE70 | STACR 2022-HQA3 M2 | 2 | B | 1 | E |
35564KP60 | STACR 2023-DNA1 M2B | 2 | C | 1 | E |
35564KP94 | STACR 2023-DNA1 M2 | 2 | A | 1 | E |
35564KT82 | STACR 2023-DNA2 M2B | 2 | C | 1 | E |
35564KU31 | STACR 2023-DNA2 M2 | 2 | A | 1 | E |
35564KY29 | STACR 2023-HQA1 M2B | 2 | B | 1 | E |
35564KY37 | STACR 2023-HQA1 M2 | 2 | A | 1 | E |
About Freddie Mac Single-Family Credit Risk Transfer
Freddie Mac’s Investment & Capital Markets Credit Risk Transfer (CRT) programs transfer credit risk away from U.S. taxpayers to global private capital via securities and (re)insurance policies, providing stability, liquidity and affordability to the U.S. housing market. The GSE Single-Family CRT market was founded when Freddie Mac issued the first STACR ® (Structured Agency Credit Risk) notes in July 2013. In November 2013, ACIS ® (Agency Credit Insurance Structure ®) was introduced. Today, the industry-leading and award-winning programs attract institutional investors and (re)insurance companies worldwide. For specific STACR and ACIS transaction data, visit Clarity Data Intelligence ®.
About Freddie Mac
Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability, affordability and equity in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | LinkedIn | Facebook| X | Instagram | YouTube
MEDIA CONTACT:
Fred Solomon
703-903-3861
Frederick_Solomon@FreddieMac.com
INVESTOR CONTACT:
Christian Valencia
571-382-4236
Source: Freddie Mac
- Forex2 years ago
Forex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Unbiased review of Pocket Option broker
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies